Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks
Background: Phenotypic and genotypic correlates of antiviral response (AR) derived from clinical investigation characterize an antiretroviral’s (ART) ability to inhibit HIV. The VIKING-3 and VIKING-4 (V3/4) studies examined DTG 50mg twice-daily in patients with resistance to multiple ART’s, including integrase inhibitors (INI). Baseline Integrase (IN) genotypes and phenotypes were assessed to identify correlates to AR.…